COX2 Acetylating Composition for Amyloid-β Clearance and Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for neurodegenerative diseases, such as Alzheimer's, fail to effectively address the accumulation of amyloid-β plaques and the dysregulation of microglia, leading to chronic inflammation and cognitive impairment, as the role of sphingosine kinase (SphK1) in neuroinflammatory responses has not been fully understood.
Innovation Solution
A pharmaceutical composition using a COX2 acetylating agent, specifically targeting the 565th serine residue of COX2, is developed to enhance SphK1 expression and activity, promoting the secretion of neuroinflammatory resolution factors like SPMs, thereby improving Aβ phagocytosis and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for neurodegenerative diseases are used, then general symptom management is provided, but they fail to effectively address amyloid-β plaque accumulation and microglia dysregulation
Solution Approach 1:
The patent changes the biochemical parameter of COX2 by inducing acetylation at the S565 residue, which transforms the enzyme's function from producing pro-inflammatory prostaglandins to producing anti-inflammatory SPMs. This parameter change (acetylation modification) directly addresses the harmful chronic inflammation while effectively reducing amyloid-β accumulation through enhanced microglia function
Solution Approach 2:
The patent introduces an intermediary mechanism where COX2 acetylation serves as the key mediator between SphK1 activation and the production of neuroprotective SPMs. This intermediary transformation converts the inflammatory pathway into an anti-inflammatory resolution pathway, simultaneously addressing both amyloid-β clearance and inflammation reduction
2Reliability
If microglia function is restored through SPM secretion, then neuroinflammation is resolved and Aβ phagocytosis is improved, but this requires specific biochemical modification of COX2
Solution Approach 1:
The patent applies parameter change by modifying the post-translational modification state of COX2 (acetylation at S565), which switches the enzyme's catalytic output from pro-inflammatory to anti-inflammatory mediators. This single parameter change simplifies the complex requirement by focusing on a specific biochemical modification that triggers the entire protective cascade
Solution Approach 2:
The patent enables self-service by utilizing the endogenous COX2 enzyme system, which when acetylated, automatically produces SPMs that resolve inflammation and enhance microglia function. The body's own enzymatic system is harnessed and redirected through acetylation to provide neuroprotection without requiring external administration of complex therapeutic agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The COX2 acetylating agent increases COX2 acetylation, enhancing the secretion of neuroinflammatory resolution factors, which improves microglia function, reduces Aβ deposition, and ameliorates neurodegenerative lesions and cognitive impairment in animal models of Alzheimer's, Niemann-Pick, and amyotrophic lateral sclerosis.
Implementation Method 1
COX2 acetylating agent, specifically targeting the 565th serine residue of COX2, is developed to enhance SphK1 expression and activity
Data Source
Figure 1A~1B
Figure 1C
Figure 1D
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a COX2 acetylating agent as an active ingredient and, more particularly, to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising, as an active ingredient, a COX2 acetylating agent which exhibits an effect of inhibiting the deposition of amyloid-β in brain neurons, reducing excessive neuroinflammatory responses, and increasing the phagocytosis of amyloid-β in microglial cells. The pharmaceutical composition for preventing or treating neurodegenerative diseases comprising the COX2 acetylating agent as an active ingredient has the effects of alleviating neuroinflammation by promoting COX2 acetylation in neurons and secreting specialized pro-resolving mediators (SPMs) and thus, can be very useful in the development of a preventive or therapeutic agent for neurodegenerative diseases.